Drug Profile
SB 318
Alternative Names: SB-318Latest Information Update: 30 Mar 2022
Price :
$50
*
At a glance
- Originator Sangamo Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Iduronidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Mucopolysaccharidosis I